Physician profile
Yan Zhou
NPI 1407096217
$2,584.96
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,950 · 2020: $251 · 2021: $174 · 2022: $210.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $369.17 | 2019-2022 | |
| Lilly USA, LLC | $250.80 | 2019-2021 | |
| Verastem, INC. | $246.60 | 2019 | |
| Pfizer INC. | $236.66 | 2019-2020 | |
| Amgen INC. | $229.00 | 2019-2022 | |
| Seagen INC. | $148.88 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $144.41 | 2019-2020 | |
| Janssen Biotech, INC. | $139.47 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $99.54 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.84 | 2019 | |
| Emd Serono, INC. | $70.58 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $70.38 | 2019 | |
| Celgene Corporation | $67.10 | 2019-2022 | |
| Rigel Pharmaceuticals, INC. | $59.69 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $52.33 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $51.00 | 2020-2022 | |
| Lexicon Pharmaceuticals, INC. | $50.71 | 2019 | |
| Taiho Oncology, INC. | $47.44 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $41.50 | 2019 | |
| Astellas Pharma US INC | $34.95 | 2019-2020 | |
| Genzyme Corporation | $23.97 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $17.85 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.64 | 2019 | |
| Kyowa Kirin, INC. | $13.37 | 2020 | |
| Genentech USA, INC. | $13.26 | 2019 | |
| Aurobindo Pharma USA, INC. | $12.82 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yan Zhou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.